ClariVest Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

ClariVest Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-82,200	Closed	-$661K	–	810
2018 Q2	$661K	Buy	82,200 +700	+0.9%	+$5.34K	0.01%	489
2018 Q1	$608K	Buy	81,500 +2,000	+3%	+$13.3K	0.01%	480
2017 Q4	$473K	Sell	79,500 -106,674	-57%	-$648K	0.01%	495
2017 Q3	$1.37M	Buy	186,174 +24,266	+15%	+$154K	0.03%	318
2017 Q2	$1.1M	Buy	161,908 +16,941	+12%	+$125K	0.03%	329
2017 Q1	$1.37M	Buy	+144,967	New	+$1.45M	0.03%	313

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

ClariVest Asset Management's PGNX Position: Q3 2018 in Review

ClariVest Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2018, closing a stake of 82,200 shares — an estimated $661K sold.

ClariVest Asset Management first reported a position in PGNX in Q1 2017 and held it in 6 quarters. The position peaked at $1.37M in Q3 2017. 149 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

ClariVest Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
ClariVest Asset Management sold 82,200 Progenics Pharmaceuticals Inc shares in Q3 2018, an estimated $661K.
ClariVest Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 6 quarters.
ClariVest Asset Management's Progenics Pharmaceuticals Inc position peaked at $1.37M in Q3 2017.
149 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on ClariVest Asset Management's 13F filing for Q3 2018, filed 7 Nov 2018.